KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Assets: 2019-2025

Historic Assets for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $19.3 billion.

  • Royalty Pharma's Assets rose 7.23% to $19.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 billion, marking a year-over-year increase of 7.23%. This contributed to the annual value of $18.2 billion for FY2024, which is 11.24% up from last year.
  • As of Q3 2025, Royalty Pharma's Assets stood at $19.3 billion, which was up 5.59% from $18.3 billion recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Assets ranged from a high of $19.3 billion in Q3 2025 and a low of $15.9 billion during Q3 2023.
  • Its 3-year average for Assets is $17.4 billion, with a median of $17.6 billion in 2025.
  • Per our database at Business Quant, Royalty Pharma's Assets declined by 10.28% in 2023 and then climbed by 13.79% in 2024.
  • Royalty Pharma's Assets (Quarterly) stood at $17.5 billion in 2021, then fell by 4.01% to $16.8 billion in 2022, then declined by 2.57% to $16.4 billion in 2023, then rose by 11.24% to $18.2 billion in 2024, then climbed by 7.23% to $19.3 billion in 2025.
  • Its last three reported values are $19.3 billion in Q3 2025, $18.3 billion for Q2 2025, and $17.6 billion during Q1 2025.